PT  - JOURNAL ARTICLE
AU  - Vicky Caveliers
AU  - Hendrik Everaert
AU  - Christy S. John
AU  - Tony Lahoutte
AU  - Axel Bossuyt
TI  - Sigma Receptor Scintigraphy with <em>N</em>-[2-(1′-Piperidinyl)Ethyl]-3-<sup>123</sup>I-Iodo-4-Methoxybenzamide of Patients with Suspected Primary Breast Cancer: First Clinical Results
DP  - 2002 Dec 01
TA  - Journal of Nuclear Medicine
PG  - 1647--1649
VI  - 43
IP  - 12
4099  - http://jnm.snmjournals.org/content/43/12/1647.short
4100  - http://jnm.snmjournals.org/content/43/12/1647.full
SO  - J Nucl Med2002 Dec 01; 43
AB  - The aim of this study was to investigate the potential of a new iodobenzamide, N-[2-(1′-piperidinyl)ethyl]-3-123I-iodo-4-methoxybenzamide (P-123I-MBA), to visualize primary breast tumor in humans in vivo. Tumor accumulation of benzamides is based on a preferential binding to sigma receptors that are overexpressed on breast cancer cells. Methods: P-123I-MBA (148–185 MBq) was administered to 12 patients with a mammographically suspicious breast mass. Two hours after administration, whole-body and spot images of the healthy and the diseased breast were obtained. Results: A focal increased tracer accumulation was observed in 8 of 10 patients with histologically confirmed breast cancer (mean tumor-to-background ratio, 2.04). No uptake was seen in a case of lymphatic adenitis. Conclusion: This preliminary patient study shows that P-123I-MBA accumulates in most breast tumors in vivo. Future work should focus on the relationship between P-123I-MBA uptake and the proliferative activity of cells to anticipate use of this technique as a tool to noninvasively assess the degree of tumor proliferation.